StockMarketWire.com - Gene and cell therapy group Oxford Biomedica said it had signed a manufacturing and licensing agreement with US biotechnology company Beam Therapeutics.
The pact granted Beam a non-exclusive license to Oxford Biomedica's LentiVector platform for its application in next generation CAR-T programmes in oncology and would put in place a three-year clinical supply agreement.
Cambridge, Massachusetts-based Beam developed precision genetic medicines through the use of base editing.
Oxford Biomedica would receive an undisclosed upfront payment, as well as payments related to development and manufacturing of lentiviral vectors for use in clinical trials.
Payments would also be related to certain development and regulatory milestones for products sold by Beam.
Oxford Biomedica said it was currently working on one pre-clinical programme with Beam, with the agreement allowing the parties to initiate additional projects in the future.
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.